A pilot study of interleukin-11 in subjects with chronic hepatitis C and advanced liver disease nonresponsive to antiviral therapy

American Journal of Gastroenterology

Volumn 99, Issue 12, 2004, Pages 2359-2364

  Lawitz, Eric J ^a   Hepburn, Matthew J ^b   Casey, Thomas J ^b  

^a Alamo Medical Research   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; INTERLEUKIN 11; RECOMBINANT INTERFERON; RECOMBINANT INTERLEUKIN 11; RIBAVIRIN;

ADULT; AGED; ANTIVIRAL ACTIVITY; ARTHRALGIA; ARTICLE; CHRONIC DISEASE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; EVALUATION; FEMALE; HEADACHE; HEPATITIS; HEPATITIS C; HISTOPATHOLOGY; HUMAN; LEG EDEMA; LIVER BIOPSY; LIVER DISEASE; MALE; OPEN STUDY; PILOT STUDY; PRIORITY JOURNAL; SCORING SYSTEM; SIDE EFFECT;

ADULT; AGED; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-11; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PILOT PROJECTS; PLATELET COUNT; POLYMERASE CHAIN REACTION; RECOMBINANT PROTEINS; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 11144301728     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2004.40047.x     Document Type: Article

References (41)

1. Wasley A, Alter MJ. Epidemiology of hepatitis C: Geographic differences and temporal trends. Semin Liver Dis 2000;20:1-16.
2. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;19:556-62.
3. Dev AT, McCaw R, Sundararajan V, et al. Southeast Asian patients with chronic hepatitis C: The impact of novel genotypes and race on treatment outcome. Hepatology 2002;36:1259-65.
4. Seeff LB, Hoofnagle JH. Appendix: The National Institutes of Health Consensus Development Conference Management of hepatitis C 2002. Clin Liver Dis 2003;7:261-87.
5. Zoulim F, Chevallier M, Maynard M, et al. Clinical consequences of hepatitis C virus infection. Rev Med Virol 2003;13:57-68.
6. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002;36(5 suppl 1):S35-S46.
7. Jacobson Brown PM, Neuman MG. Immunopathogenesis of hepatitis C viral infection: Th1/Th2 responses and the role of cytokines. Clin Biochem 2001;34:167-71.
8. Napoli J, Bishop GA, McGuinness PH, et al. Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines. Hepatology 1996;24:759-65.
9. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med 1989;321:1501-6.
10. Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989;321:1506-10.
11. Marcellin P, Boyer N, Giostra E, et al. Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: A multicenter randomized controlled trial from France. Hepatology 1991;13:393-7.
12. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1493-9.
13. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-92.
14. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon a2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998;352:1426-32.
15. Forton DM, Wright M, Knapp S, et al. New insights into hepatitis C. Clin Med 2002;2:554-9.
16. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
17. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001;358:958-65.
18. Isaacs C, Robert NJ, Bailey FA, et al. Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin. J Clin Oncol 1997;15:3368-77.
19. Gordon MS, McCaskill-Stevens WJ, Battiato LA, et al. A phase I trial of recombinant human interleukin-11 (neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy. Blood 1996;87:3615-24.
20. Tepler I, Elias L, Smith JW 2, et al. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 1996;87:3607-14.
21. Trepicchio WL, Bozza M, Pedneault G, et al. Recombinant human IL-11 attenuates the inflammatory response through down-regulation of proinflammatory cytokine release and nitric oxide production. J Immunol 1996;157:3627-34.
22. Hill GR, Cooke KR, Teshima T, et al. Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation. J Clin Invest 1998;102:115-23.
23. Trepicchio WL, Ozawa M, Walters IB, et al. Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions. J Clin Invest 1999;104:1527-37.
24. Opal SM, DePalo VA. Anti-inflammatory cytokines. Chest 2000;117:1162-72.
25. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-5.
26. Fontaine H, Nalpas B, Poulet B, et al. Hepatitis activity index is a key factor in determining the natural history of chronic hepatitis C. Hum Pathol 2001;32:904-9.
27. Neumega® (oprelvekin) [prescribing information]. Cambridge, MA: Genetics Institute, Inc., 2003.
28. Cerny A, Chisari FV. Pathogenesis of chronic hepatitis C: Immunological features of hepatic injury and viral persistence. Hepatology 1999;30:595-601.
29. Masaki N, Fukushima S, Hayashi S. Lower Th-1/Th-2 ratio before interferon therapy may favor long-term virological responses in patients with chronic hepatitis C. Dig Dis Sci 2002;47:2163-9.
30. Nelson DR, Tu Z, Soldevila-Pico C, et al. Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect. Hepatology 2003;38:859-68.
31. Sreenarasimhaiah J, Jaramillo A, Crippin J, et al. Lack of optimal T-cell reactivity against the hepatitis C virus is associated with the development of fibrosis/cirrhosis during chronic hepatitis. Hum Immunol 2003;64:224-30.
32. Yano M, Kumada H, Kage M, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996;23:1334-40.
33. Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002;122:1303-13.
34. Artz AS, Ershler WB, Rustgi V. Interleukin-11 for thrombocytopenia associated with hepatitis C. J Clin Gastroenterol 2001;33:425-26.
35. Ghalib R, Levine C, Hassan M, et al. Recombinant human interleukin-11 improves thrombocytopenia in patients with cirrhosis. Hepatology 2003;37:1165-71.
36. de Araujo ES, Cavalheiro NP, Cubero Leitao RM, et al. Hepatitis C viral load does not predict disease outcome: Going beyond numbers. Rev Inst Med Trop Sao Paulo 2002;44:71-8.
37. De Moliner L, Pontisso P, De Salvo GL, et al. Serum and liver HCV RNA levels in patients with chronic hepatitis C: Correlation with clinical and histological features. Gut 1998;42:856-60.
38. Freeman AJ, Law MG, Kaldor JM, et al. Predicting progression to cirrhosis in chronic hepatitis C virus infection. J Viral Hepat 2003;10:285-93.
39. Nguyen TT, Sedghi-Vaziri A, Wilkes LB, et al. Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection. J Viral Hepat 1996;3:75-8.
40. Pontisso P, Bellati G, Brunetto M, et al. Hepatitis C virus RNA profiles in chronically infected individuals: Do they relate to disease activity? Hepatology 1999;29:585-9.
41. Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002;97:2614-8.